Eloxx Pharmaceuticals Inc. (ELOX) and Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) Comparison side by side

Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) and Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals Inc. 7 0.00 21.79M -1.45 0.00
Salarius Pharmaceuticals Inc. 4 0.00 2.98M -4.24 0.00

Demonstrates Eloxx Pharmaceuticals Inc. and Salarius Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals Inc. 332,549,905.38% -119.8% -83.7%
Salarius Pharmaceuticals Inc. 76,982,691.81% -89.9% -72.5%

Risk & Volatility

Eloxx Pharmaceuticals Inc. is 95.00% more volatile than Standard & Poor’s 500 due to its 1.95 beta. Competitively, Salarius Pharmaceuticals Inc. is 37.00% more volatile than Standard & Poor’s 500, because of the 1.37 beta.

Insider and Institutional Ownership

Eloxx Pharmaceuticals Inc. and Salarius Pharmaceuticals Inc. has shares owned by institutional investors as follows: 54.5% and 6.3%. Insiders owned roughly 0.4% of Eloxx Pharmaceuticals Inc.’s shares. Comparatively, 0.6% are Salarius Pharmaceuticals Inc.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eloxx Pharmaceuticals Inc. -1.72% -0.19% -18.83% -47.38% -61.17% -57.29%
Salarius Pharmaceuticals Inc. 0% -6.98% -50% -70.34% -60% -51.5%

For the past year Salarius Pharmaceuticals Inc. has weaker performance than Eloxx Pharmaceuticals Inc.

Summary

Eloxx Pharmaceuticals Inc. beats on 6 of the 9 factors Salarius Pharmaceuticals Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.